5 Einträge gefunden

1. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial

   1. Döhner, Hartmut
   2. Weber, Daniela
   3. Krzykalla, Julia
   4. Fiedler, Walter
   5. Kühn, Michael W M
   6. Schroeder, Thomas
   7. Mayer, Karin

   2023 - Forschungsinformationssystem des UKE
2. Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications

   1. Döhner, Hartmut
   2. Weber, Daniela
   3. Krzykalla, Julia
   4. Fiedler, Walter
   5. Wulf, Gerald Georg
   6. Salih, Helmut R
   7. Lübbert, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

   1. Teich, Katrin
   2. Krzykalla, Julia
   3. Kapp-Schwoerer, Silke
   4. Gaidzik, Verena I
   5. Schlenk, Richard F
   6. Paschka, Peter
   7. Weber, Daniela

   2021 - Forschungsinformationssystem des UKE
4. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

   1. Schlenk, Richard F
   2. Paschka, Peter
   3. Krzykalla, Julia
   4. Weber, Daniela
   5. Kapp-Schwoerer, Silke
   6. Gaidzik, Verena I
   7. Leis, Claudia

   2020 - Forschungsinformationssystem des UKE
5. Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

   1. Schlenk, Richard F
   2. Weber, Daniela
   3. Fiedler, Walter
   4. Salih, Helmut R
   5. Wulf, Gerald
   6. Salwender, Hans
   7. Schroeder, Thomas

   2019 - Forschungsinformationssystem des UKE